Brief: Sprint Bioscience Q4 Operating Loss Narrows To SEK 4.9 Million
Feb 12 (Reuters) - Sprint Bioscience AB SPRINT.ST :
* Q4 NET SALES SEK 16.3 MILLION VERSUS SEK 10.9 MILLION YEAR
AGO
* Q4 OPERATING LOSS SEK 4.9 MILLION VERSUS LOSS SEK 5.1
MILLION
YEAR AGO
* PROPOSES THAT NO DIVIDEND BE PAID FOR FINANCIAL YEAR 2024
Source text: ID:nMFN8pyYPS
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln